Today's After-Hours Stock Movers

ContraFect Corporation (Nasdaq: CFRX) 36.2% HIGHER; has been awarded a cost-share contract from the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services (HHS). Under the terms of the contract, the Company will receive $9.8 million in initial funding and up to an additional $77.0 million. The initial funding will be used to support ContraFects ongoing pivotal Phase 3 DISRUPT (Direct Lysis of Staph aureus Resistant Pathogen Trial) superiority study of exebacase in patients with Staph aureus bacteremia, including right-sided endocarditis. Under the terms of the agreement, and if supported by Phase 3 DISRUPT study data, BARDA may provide the Company with additional funding upon achievement of key milestones to continue the advancement of exebacase through FDA product approval and completion of post-approval commitments.

Marker Therapeutics, Inc. (Nasdaq: MRKR) 22.1% LOWER; announced that it has commenced an underwritten public offering of shares of its common stock.

Novavax, Inc. (Nasdaq: NVAX) 22.2% HIGHER; announced final efficacy of 96.4% against mild, moderate and severe disease caused by the original COVID-19 strain in a pivotal Phase 3 trial in the United Kingdom (U.K.) of NVXCoV2373, the company's vaccine candidate. The company also announced the complete analysis of its Phase 2b trial taking place in South Africa, with efficacy of 55.4% among the HIV- negative trial participants in a region where the vast majority of strains are B1.351 escape variants. Across both trials, NVX-CoV2373 demonstrated 100% protection against severe disease, including all hospitalization and death. Both studies achieved their statistical success criteria. Today's final analyses build on the successful interim results announced in January 2021, adding substantially more COVID-19 cases and statistical power.

Poshmark Inc. (NASDAQ: POSH) 14.3% LOWER; reported Q4 non-GAAP EPS of $0.05, versus ($1.18) reported last year. Revenue for the quarter came in at $69.3 million, versus $54.7 million reported last year. Poshmark Inc. sees Q1 2021 revenue of $75.5-77.5 million.

Funko (NASDAQ: FNKO) 12.2% HIGHER; reported Q4 EPS of $0.25, $0.11 better than the analyst estimate of $0.14. Revenue for the quarter came in at $226.5 million versus the consensus estimate of $195.67 million. 2021 Net sales growth of 25% to 30%.

Seelos Therapeutics (NASDAQ: SEEL) 11.8% HIGHER; BTIG initiates coverage on with a Buy rating and a price target of $14.00.

Vail Resorts (NYSE: MTN) 9.7% HIGHER; reported Q2 EPS of $3.62, $1.36 better than the analyst estimate of $2.26. Revenue for the quarter came in at $684.6 million versus the consensus estimate of $641.95 million.

Ulta Beauty (NASDAQ: ULTA) 6.8% LOWER; announced leadership changes to drive continuity and continued momentum, all effective in June. Dave Kimbell, president, will succeed Mary Dillon as chief executive officer and will be nominated to stand for election to the companys board of directors at the 2021 annual stockholders meeting. Dillon will transition to the role of executive chair of the board of directors. Kecia Steelman, currently chief store operations officer, will be elevated to the role of chief operating officer.

Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) 5.7% LOWER; announced today that it intends to offer shares of its common stock for sale in an underwritten public offering.

Microvision (NASDAQ: MVIS) 5.5% HIGHER; reported Q4 EPS of ($0.02), versus ($0.03) reported last year. Revenue for the quarter came in at $395 thousand versus the consensus estimate of $400 thousand.